Sakuma Yuji, Sakurai Shinji, Oguni Sachiko, Hironaka Mitsugu, Saito Ken
Department of Pathology, Jichi Medical School, Kawachi-gun, Tochigi 329-0498, Japan.
Cancer Sci. 2003 Jun;94(6):486-91. doi: 10.1111/j.1349-7006.2003.tb01470.x.
Expression and gain-of-function mutation of the c-kit gene, that encodes a receptor tyrosine kinase (KIT), have been reported in mast cell tumors and gastrointestinal stromal tumors (GISTs). Among human testicular germ cell tumors (GCTs), seminomas and seminoma components of mixed GCTs have also been shown to express KIT, but only one study has found the c-kit gene mutation at exon 17 in seminoma. To elucidate the frequency and location of the c-kit gene mutation of testicular GCTs, we analyzed the whole coding region of the c-kit complementary DNA along with 4 mutational hot spots (exons 9, 11, 13 and 17) of the c-kit genomic DNA by polymerase chain reaction and direct sequencing. Somatic mutations were found in 4 pure seminomas of 34 testicular GCTs (11.8%). One mutation was found in exon 11 (W557R) and the others were observed in exon 17 (D816H and D816V). These types of mutations were reported in GISTs (W557R), seminoma (D816H) and mastocytosis (D816V) and were considered to be gain-of-function mutations, although there were no differences of any clinicopathological factors or outcome between patients with and without mutations. Additionally, we also demonstrated coexpression of Gly-Asn-Asn-Lys510-513 (GNNK) + and GNNK - isoforms of the c-kit gene with dominance of the GNNK - transcript in all testicular GCTs. The mutations and/or preferential expression of GNNK - isoform of the c-kit gene might play an important role in the development of testicular GCTs, and these tumors may also be targets for STI571, which is a promising drug for advanced and metastatic GISTs.
编码受体酪氨酸激酶(KIT)的c-kit基因的表达及功能获得性突变已在肥大细胞瘤和胃肠道间质瘤(GIST)中被报道。在人类睾丸生殖细胞肿瘤(GCT)中,精原细胞瘤以及混合性GCT中的精原细胞瘤成分也已显示表达KIT,但仅有一项研究在精原细胞瘤中发现第17外显子的c-kit基因突变。为阐明睾丸GCT中c-kit基因突变的频率及位置,我们通过聚合酶链反应和直接测序分析了c-kit互补DNA的整个编码区以及c-kit基因组DNA的4个突变热点(第9、11、13和17外显子)。在34例睾丸GCT中的4例纯精原细胞瘤(11.8%)中发现了体细胞突变。1例突变位于第11外显子(W557R),其他突变见于第17外显子(D816H和D816V)。这些突变类型在GIST(W557R)、精原细胞瘤(D816H)和肥大细胞增多症(D816V)中均有报道,并且被认为是功能获得性突变,尽管有或无突变的患者之间在任何临床病理因素或预后方面均无差异。此外,我们还证实在所有睾丸GCT中c-kit基因的Gly-Asn-Asn-Lys510-513(GNNK)+和GNNK - 异构体共表达,且GNNK - 转录本占优势。c-kit基因的GNNK - 异构体的突变和/或优先表达可能在睾丸GCT的发生发展中起重要作用,并且这些肿瘤也可能是STI571的作用靶点,STI571是一种用于晚期和转移性GIST的有前景的药物。